care setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer personnel). person (3–5). If untreated, death from EVD can be rapid, usually occurring 7–10 days after the onset of symptoms (6–9). Methods During March 2020–November 2021, the Ebola Vaccine Work Group met at least monthly via conference call to review and discuss relevant evidence regarding expansion of recommendations to the two populations of interest using the Evidence to Recommendations framework.† SPTCs. SPTCs (formerly known as state-designated Ebola treatment centers) are health care facilities, designated by states, that intend to receive and can provide care for a patient with suspected or confirmed EVD for the duration of their illness (10). Currently, there are approximately 55 U.S. SPTCs, with 100–150 health care personnel at each facility. Upon the recommendation of the Council for State and Territorial Epidemiologists, the name “special pathogens treatment centers” replaced “state-designated Ebola treatment centers” because many of these centers have the capability to treat patients with other diseases in addition to EVD. LRN facilities. LRN is a large network of laboratories throughout the United States; these facilities aim to rapidly respond to biologic and chemical threats and other public health emergencies. Within the LRN, there are currently 58 laboratories that have the capacity to test for Ebola virus, with up to 15 persons at each facility trained to perform the testing (11). Knowledge, Attitude and Practices survey. A Knowledge, Attitude and Practices survey was distributed to personnel at both SPTCs and LRN facilities. The purpose of the survey was to measure EVD vaccine acceptability and sentiments in these populations. Survey questions assessed perceived severity of EVD and risk for infection, interest in receiving the vaccine, and concerns about the vaccine. SPTCs and LRN facilities were provided anonymous survey website links to a point of contact at each site. The survey was distributed to the SPTCs on October 14, 2020 and to LRN facilities on † https://www.cdc.gov/vaccines/acip/recs/grade/ebola-vaccine-etr.html Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / February 25, 2022 / Vol. 71 / No. 8 291 December 29, 2020 and remained open for both populations until January 22, 2021.§ Vaccine efficacy and safety. The Ebola Vaccine Work Group relied upon Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence profiles, which provide detailed methods and results used to assess Ebola vaccine efficacy and safety.¶ These profiles were presented at the February 26, 2020, ACIP meeting. Summary of Major Findings Knowledge, Attitude and Practices survey to SPTCs and LRN facilities. Fifty-one SPTCs in 24 states were identified at the time of the survey. Among those, the survey was distributed to 49 centers; contact information was missing for two of the centers. In total, 364 survey responses were received from the SPTC population; 66 were excluded because of incompleteness, leaving 298 responses for analyses. Among SPTC respondents, 69% were women and 52% were aged ≥40 years. Thirty-nine percent of SPTC respondents self-identified as nurses and 22% as physicians. Additional health care professional groups included respiratory therapists, emergency medical technicians, advanced practice providers, laboratory technicians, and others. Sixty-two LRN facilities (the number of facilities capable of testing for Ebola virus at the time of the survey) were identified. Ninety-six survey responses were received from this population; 26 were excluded because of incompleteness, leaving 70 responses included for analyses. Among LRN respondents, 64% were women and 76% were aged ≥40 years. Most LRN respondents (64%) self-identified as “laboratory scientist.” Fifty-four percent of SPTC survey respondents reported willingness to be vaccinated if they were eligible and offered the vaccine at the time of survey administration.** When given the choice to get vaccinated at different time points (i.e., when an EVD case is imported to the United States or when an EVD case is imported to their state), willingness to receive vaccine increased to 81%. When asked whether they believed that ACIP should recommend the vaccine for their population, 53% responded yes, 9% responded no, and 38% were unsure. Fifty-nine percent of LRN survey respondents reported willingness to be vaccinated if they were eligible and offered the vaccine at the time of survey administration.†† When given the § During this time, there was an Ebola outbreak in Equateur Province in the Democratic Republic of the Congo; the end of the outbreak was declared on November 18, 2020. ¶ https://www.cdc.gov/vaccines/acip/recs/grade/ebola-vaccine.html ** These respondents took the survey during October 14, 2020–January 22, 2021. During this time, there was an Ebola outbreak in Equateur Province in the Democratic Republic of the Congo; the end of the outbreak was declared on November 18, 2020. †† These respondents